In adults with overweight or obesity without diabetes, semaglutide 2.4 mg reduced body weight by 14.9% versus 2.4% with placebo at week 68.
In plain wordsIn adults with overweight or obesity, semaglutide led to 14.9% average weight loss compared with 2.4% with placebo over 68 weeks.
- Peptide
- Semaglutide
- Outcome
- DecreasePercentage change in body weight at week 68
- Study
n = 1,961
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
- Mean weight change
- −14.9%
- semaglutide
- Mean weight change
- −2.4%
- placebo
- Estimated treatment difference
- −12.4 percentage points
- semaglutide vs placebo
Source sentences
The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001).
2 context sentences(design, population, supporting numbers)
we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes
randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention